Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?1ST-LINE TREATMENTSORAFENIBLENVATINIBTHERAPYBackgroundAtezolizumab plus bevacizumab has recently been approved as a new first-line standard ...
In this study, higher TMB levels were associated with improved PFS and OS in the atezolizumab versus placebo arm in patients with PD-L1 + tumors but not in those with PD-L1– tumors. There was no information about the benefit specifically in the TMB-H (≥10 mut/Mb) population. ...
Atezolizumab + bevacizumab Anti-PD-L1 monoclonal antibody + Monoclonal antibody against VEGF Recurrent MCC Phase II(Active, not recruiting) NCT03074513 Durvalumab + tremelimumab + Poly-ICLC MCC Phase II(Completed) NCT02643303 TIL - MCC Phase II (Recruiting) NCT03935893 Zirconium Zr 89 crefmirlimab...
Furthermore, in patients with resect- able NSCLC who underwent neoadjuvant therapy with atezolizumab, it has been shown that innate immune markers such as NK cells and NK-like T cells expressing ILT2- and NKG2A in the peripheral blood before treat- ment can be used to predict MPR [56]. ...
Explore the effectiveness & safety of TECENTRIQ® (atezolizumab) for metastatic non-small cell lung cancer (mNSCLC). See full safety for more information.
Tecentriq (atezolizumab) for the treatment of advanced or metastatic urothelial cancer and metastatic non-small cell lung cancer. The decision to use this product is informed by PD-L1 expression levels in the tumors of patients. Venclexta (venetoclax) for the treatment of chronic lymphocytic leukem...
One of these, atezolizumab (Tecentriq), has been approved by the FDA for patients with certain advanced lung and bladder cancers that no longer respond to standard chemotherapy (Gold Standard 2017c). Another drug, avelumab (Bavencio), has been approved for advanced cases of urinary tract ...